New York, New York--(Newsfile Corp. - October 22, 2025) - OS Therapies Inc. (OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology ...
Ivo Carre, PhD, shares subgroup data that points to potential benefit in younger patients with high-risk MDS. The VERONA (NCT04401748) trial evaluating venetoclax with azacitidine in high-risk ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results